• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dramamine® Celebrates its 75th Anniversary by Reviving an Unexpected Partner: The Barf Bag

    4/3/24 11:57:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBH alert in real time by email

    TARRYTOWN, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- 1949 was a big year for barf, welcoming the invention of the barf bag and Dramamine®. Seventy-five years later, Dramamine, a Prestige Consumer Healthcare brand, thrives as the number one brand for motion sickness relief, but as Dramamine has risen in popularity, the use of barf bags has sadly diminished. To commemorate the joint anniversary, Dramamine® is breathing new life – not barf – into the paper product with a mission to save its fellow partner in puke.

    "The Last Barf Bag" campaign announced today by Dramamine®, alongside agency partners FCB Chicago, 360PR+ and The Shipyard, explores the cultural impact of a humble yet crucial American invention made all but defunct due to Dramamine's effectiveness in preventing unexpected upchucks. Through a new documentary, a collection of upcycled, repurposed bags and a pop-up museum exhibition, Dramamine is paying tribute to a once iconic part of our culture and history, nodding to the manufacturers, collectors, and nausea sufferers as they fill barf bags with new purpose and save their industry from irrelevance.

    "We're not saying that Dramamine has caused the demise of the barf bag, but we are saying that Dramamine is effective in minimizing their use, and we feel bad about that," said Erica Nesbitt, Senior Brand Manager of Dramamine at Prestige Consumer Health. "The 75th anniversary of both inventions felt like the right time to commemorate barf bags' contributions to culture and even rewrite what the future holds for them after Dramamine's impact has made their intended purpose all but obsolete."

    ‘The Last Barf Bag' Documentary

    The documentary short film, The Last Barf Bag: A Tribute to a Cultural Icon, explores the cultural impact of a humble but crucially useful American invention. In it, the barf bag collectors and manufacturers whose passion can be credited to saving it from extinction, meet their unlikely ally: the makers of the anti-nausea medication that threatens its existence. Directed by the filmmaking collective Sunny Sixteen (Niles Jeran, Joshua Martin, Taylor Pendleton, and Caleb Babcock), The Last Barf Bag film introduces us to doctors, pilots, historians, collectors, brand managers, suppliers, flight attendants, and even regular people discussing their barf-worthy experiences.

    ‘This is Not A Barf Bag' Limited Edition Collection

    Dramamine and barf bags have been fighting the good fight against nausea together, but the barf bag can make way for a purpose that goes way beyond catching upchucks. Consumers can get in on the crusade to save culture's cherished paper puke sacks by purchasing upcycled barf bags that can be used as puppets, chef's hats, popcorn bags, coloring canvases, vases and more. Each bag in its repurposed form will be available for purchase for $5, and bundles including a barf bag and Dramamine product will be $10 while supplies last. View the full collection here.

    Dramamine commissioned artist and creative director known for her appearance on NBC's Making It, Jessie Bearden, to display her craft on a new type of novel canvas…vintage barf bags. Bearden created a custom-made puffer coat using the colorful, patterned barf bags from around the world as material for a unique, only-of-its-kind item and exhibition piece. The puffer can be previewed at TheLastBarfBag.com today through April 17 at 12pm EST, when it will open up for one lucky consumer to secure the ultra-limited edition drop for just $7.50, a nod to the 75th anniversary milestone.

    "The unique look of vintage barf bags and their various colors and designs actually make a great template for a totally one-of-a-kind textile, and that's what inspired me to create a jacket," said Bearden. "I use a lot of unorthodox materials in my work, but a barf bag is a first! It makes me so happy knowing the piece will give a new life to these barf bags and I hope it serves as a conversation starter for the one lucky person who gets to wear it and spread the news of Dramamine's The Last Barf Bag project."

    Barf Bag Collection Exhibition

    Today in New York City for one day only, consumers and passersby can see The Last Barf Bag Exhibition in-person and watch an exclusive screening of the documentary on the day of its world premiere. The extensive collections of four of America's preeminent barf bag collectors will be on full display, including collections consisting of hundreds of bags collected over 5+ decades from around the world and even space. The exhibit will be open to the general public on April 3 from 12pm – 7pm at 437 N. Broadway.

    Following the exhibition, its collections and contents will be available to be viewed online. Consumers can pay their tributes to the barf bag's cultural impact and secure their piece of barf bag history by visiting TheLastBarfBag.com.

    Follow @DramamineOfficial for more information.

    ABOUT DRAMAMINE®

    Dramamine® is the #1 name in motion related nausea relief. Dramamine®'s range of solutions, in various forms, effectively prevent and treat nausea, dizziness, vomiting & queasiness. The brand falls under the Prestige Consumer Healthcare portfolio, which markets and distributes over-the-counter products in the U.S., Canada and Australia.

    With 75 years of experience, Dramamine® is the leader in nausea relief with a wide range of solutions created to help Americans unwanted bouts of barf. For more information on Dramamine® products, including Dramamine® Original Formula, Dramamine® Non-Drowsy, and the newest Dramamine® Ginger Chews, and for a list of retailers, visit www.Dramamine.com.

    ABOUT PRESTIGE CONSUMER HEALTHCARE INC.

    Prestige Consumer Healthcare is a leading consumer healthcare products company with sales throughout the U.S. and Canada, Australia, and in certain other international markets. The Company's diverse portfolio of brands include Monistat® and Summer's Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux's Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.



    Investor Relations Contact
    Phil Terpolilli, CFA, 914-524-6819
    [email protected]

    Primary Logo

    Get the next $PBH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PBH

    DatePrice TargetRatingAnalyst
    9/24/2025$80.00Neutral → Buy
    Sidoti
    12/9/2024$90.00Buy → Neutral
    Sidoti
    6/21/2024$65.00 → $93.00Neutral → Buy
    DA Davidson
    11/17/2022$71.00Buy
    Canaccord Genuity
    5/10/2022$65.00 → $70.00Hold → Buy
    Jefferies
    5/9/2022$63.00Perform → Outperform
    Oppenheimer
    3/11/2022$156.00 → $142.00Outperform
    BMO Capital
    11/15/2021$61.00 → $63.00Neutral
    DA Davidson
    More analyst ratings

    $PBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Prestige Consumer upgraded by Sidoti with a new price target

    Sidoti upgraded Prestige Consumer from Neutral to Buy and set a new price target of $80.00

    9/24/25 7:53:30 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer downgraded by Sidoti with a new price target

    Sidoti downgraded Prestige Consumer from Buy to Neutral and set a new price target of $90.00

    12/9/24 9:05:37 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer upgraded by DA Davidson with a new price target

    DA Davidson upgraded Prestige Consumer from Neutral to Buy and set a new price target of $93.00 from $65.00 previously

    6/21/24 7:05:28 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Prestige Consumer Healthcare Inc.

    SCHEDULE 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    2/13/26 10:52:39 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Prestige Consumer Healthcare Inc.

    10-Q - Prestige Consumer Healthcare Inc. (0001295947) (Filer)

    2/5/26 6:09:49 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)

    2/5/26 6:04:13 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Senior VP Operations Zerillo Jeffrey sold $65,930 worth of shares (1,000 units at $65.93), decreasing direct ownership by 2% to 41,048 units (SEC Form 4)

    4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

    2/13/26 4:37:31 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Rosado Jose Luis was granted 3,426 shares, increasing direct ownership by 34,260% to 3,436 units (SEC Form 4)

    4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

    1/29/26 4:02:16 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Rosado Jose Luis claimed ownership of 10 shares (SEC Form 3)

    3 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

    1/29/26 4:01:24 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results

    Revenue of $283.4 million in Q3, ahead of outlookDiluted EPS of $0.97 in Q3 and Adjusted Diluted EPS of $1.14, versus prior year Q3 Diluted EPS of $1.22Repurchased approximately 0.8 million shares opportunistically in Q3Successfully closed acquisition of eye care supplier Pillar5 Pharma, Inc. in December, as expectedNarrowing Outlook Range of Fiscal 2026 Revenue and Adjusted Diluted EPS TARRYTOWN, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and nine months ended December 31, 2025. "We exceeded our third quarter revenue outlook and delivered solid profitability in the quarter, which

    2/5/26 6:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earnings Results Date and Participation in the ICR Conference

    TARRYTOWN, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the "Company" or "Prestige") (NYSE:PBH) today announced it will issue its fiscal 2026 third quarter earnings release on Thursday, February 5, 2026 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.   To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recomme

    1/12/26 8:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2026 Results

    Revenue of $274.1 million in Q2, ahead of outlookDiluted EPS of $0.86 in Q2 and Adjusted Diluted EPS of $1.07, versus prior year Q2 Diluted EPS of $1.09Repurchased approximately 1.1 million shares opportunistically in Q2Fiscal 2026 revenue outlook unchanged; Adjusted Diluted EPS outlook updated to $4.54 to $4.58, high end of previous range TARRYTOWN, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first six months ended September 30, 2025. "Our second quarter results surpassed our sales and earnings expectations helped primarily by Clear Eyes® supply timing and the timing of certain retailer

    11/6/25 6:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Leadership Updates

    Live Leadership Updates

    View All

    Better For You Wellness Announces Results from Its February 5, 2022, Board of Directors Meeting

    Better For You Wellness Establishes Strategic Advisory Committee with Industry Leaders and MoreColumbus, Ohio--(Newsfile Corp. - February 10, 2022) - Better For You Wellness, Inc. (OTCQB:BFYW) ("Better For You Wellness" or the "Company"), an Ohio-based company focused on the rapidly-growing $1.5T wellness industry, is pleased to announce the results of the Meeting of the Board of Directors that took place on February 5, 2022, via video conference (the "Board Meeting"). The seven members of the Company's Board of Directors (the "Board") include Ian James, Stephen Letourneau, Montel Williams, Christina Jefferson, Joseph Watson, David Deming, and Dr. Nicola Finley, MD.Establishment of Strategic

    2/10/22 3:58:00 PM ET
    $LEAF
    $PBH
    $SPTN
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Prestige Consumer Healthcare Inc.

    SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    2/14/24 10:11:25 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Prestige Consumer Healthcare Inc.

    SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    2/14/24 7:09:49 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Prestige Consumer Healthcare Inc. (Amendment)

    SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    2/13/24 5:12:15 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Financials

    Live finance-specific insights

    View All

    Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results

    Revenue of $283.4 million in Q3, ahead of outlookDiluted EPS of $0.97 in Q3 and Adjusted Diluted EPS of $1.14, versus prior year Q3 Diluted EPS of $1.22Repurchased approximately 0.8 million shares opportunistically in Q3Successfully closed acquisition of eye care supplier Pillar5 Pharma, Inc. in December, as expectedNarrowing Outlook Range of Fiscal 2026 Revenue and Adjusted Diluted EPS TARRYTOWN, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and nine months ended December 31, 2025. "We exceeded our third quarter revenue outlook and delivered solid profitability in the quarter, which

    2/5/26 6:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Announces Fiscal 2026 Third Quarter Earnings Results Date and Participation in the ICR Conference

    TARRYTOWN, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the "Company" or "Prestige") (NYSE:PBH) today announced it will issue its fiscal 2026 third quarter earnings release on Thursday, February 5, 2026 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET.   To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recomme

    1/12/26 8:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2026 Results

    Revenue of $274.1 million in Q2, ahead of outlookDiluted EPS of $0.86 in Q2 and Adjusted Diluted EPS of $1.07, versus prior year Q2 Diluted EPS of $1.09Repurchased approximately 1.1 million shares opportunistically in Q2Fiscal 2026 revenue outlook unchanged; Adjusted Diluted EPS outlook updated to $4.54 to $4.58, high end of previous range TARRYTOWN, N.Y., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its second quarter and first six months ended September 30, 2025. "Our second quarter results surpassed our sales and earnings expectations helped primarily by Clear Eyes® supply timing and the timing of certain retailer

    11/6/25 6:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care